Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation

World Journal of Urology

Volumn 26, Issue 5, 2008, Pages 509-516

  Cao, Wengang ^a   Shiverick, Kathleen T ^b   Namiki, Kazunori ^a   Sakai, Yoshihisa ^a   Porvasnik, Stacy ^a   Urbanek, Cydney ^a   Rosser, Charles J ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Bcl 2; Bortezomib; Docetaxel; Prostatecancer; Radiation

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; DOCETAXEL; PROTEIN BCL 2; PYRAZINE DERIVATIVE; RADIOSENSITIZING AGENT; TAXOID;

ARTICLE; BIOSYNTHESIS; DOWN REGULATION; DRUG EFFECT; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; RADIATION EXPOSURE; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DOWN-REGULATION; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; RADIATION-SENSITIZING AGENTS; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 53549129722     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0289-5     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics. CA Cancer J Clin 57:43-66
2. Merrill RM, Brawley OW (1997) Prostate cancer incidence and mortality rates among white and black men. Epidemiology 8:126-131
3. Shipley WU, Verhey LJ, Munzenrider JE et al (1995) Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radat Oncol Biol Phys 32:3-12
4. Pollack A, Zagars GK, Starkschall G et al (1996) Conventional vs. conformal radiotherapy for prostate cancer. Preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 34:555-564
5. Bagshaw MA, Kaplan ID, Cox RC (1993) Prostate cancer. Radiation therapy for localized disease. Cancer 71:939-952
6. Pollack A, Zagars GK, Smith LG et al (2000) Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904-3911
7. Pilepich MV, Perez CA, Walz BJ et al (1981) Complications of definitive radiotherapy for carcinoma of the prostate. Int. J Radiat Oncol Biol Phys 7:1341-1348
8. Shipley WU, Zietman AL, Hanks GE et al (1994) Treatment-related sequelae following external beam radiation for prostate cancer: A review with an update in patients with stage T1 and T2 tumors. J Urol 152:1799-1805
9. An J, Chervin AS, Nie A et al (2007) Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 26:652-661
10. Mackey TJ, Borkowski A, Amin P et al (1998) bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52:1085-1090
11. Rakozy C, Grignon DJ, Sarkar FH et al (1998) Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy. Mod Pathol 11:892-899
12. Grossfeld GD, Olumi AF, Connolly JA et al (1998) Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol 159:1437-1443
13. Huang A, Gandour-Edwards R, Rosenthal SA et al (1998) p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 51:346-351
14. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
15. Petrylak DP, Tangen CM, Hussain MH et al (2007) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
16. Kraus LA, Samuel SK, Schmid SM et al (2003) The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Invest New Drugs 21:259-268
17. Fennell DA, Chacko A, Mutti L (2008) BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 27(9):1189-1197
18. Rosser CJ, Tanaka M, Pisters LL et al (2004) Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther 11:273-279
19. Tanaka M, Rosser CJ, Grossman HB (2005) PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. Cancer Detect Prev 29:170-174
20. Anai S, Goodison S, Shiverick K et al (2007) Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther 6:101-111
21. Rosser CJ, Reyes AO, Vakar-Lopez F et al (2003) Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys 56:1-6
22. Fernandez A, Udagawa T, Schwesinger C, Beecken W, Achilles-Gerte E, McDonnell T et al (2001) Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 93:208-213
23. Pollack A, Cowen D, Troncoso P et al (2003) Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 97:1630-1638
24. D'Amico AV, Whittington R et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974
25. Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097-1105
26. Zelefsky MJ, Fuks Z, Wolfe T et al (1998) Locally advanced prostatic cancer: Long-term toxicity outcome after three-dimensional conformal radiation therapy - a dose-escalation study. Radiology 209:169-174
27. Yvon AC, Wadsworth P, Jordan MA (1999) Taxol suppresses dynamics of individual microtubules in living human tumor cells. Am Soc Cell Biol 10:947-959
28. Lyseng-Williamson KA, Fenton C (2005) Docetaxel: A review of its use in metastatic breast cancer. Drugs 65:2513-2531
29. Jones SE, Savin MA, Holmes FA et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387
30. Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P, Cusack JC Jr (2001) Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50:183-193
31. Zamzami N, Brenner C, Marzo I et al (1998) Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 16:2265-2282
32. Bolla M, Collette L, Blank L, Warde P et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360:103-106